Results from both pair-wise as well as network meta-analysis of RCTs and observational studies suggest that the use of incretin mimetics, specifically DPP-4 inhibitors were associated with the lowest incidence and rate of hypoglycemia, when compared with sulfonylureas. This evidence concerns the gene GCG and Hypoglycemia.